IL114726A - Pharmaceutical compositions containing 12-hydroxyibogamine or an ester thereof for treatment of craving for and dependency on chemical substances and withdrawal symptoms and the novel esters of 12-hydroxyibogamine - Google Patents
Pharmaceutical compositions containing 12-hydroxyibogamine or an ester thereof for treatment of craving for and dependency on chemical substances and withdrawal symptoms and the novel esters of 12-hydroxyibogamineInfo
- Publication number
- IL114726A IL114726A IL11472695A IL11472695A IL114726A IL 114726 A IL114726 A IL 114726A IL 11472695 A IL11472695 A IL 11472695A IL 11472695 A IL11472695 A IL 11472695A IL 114726 A IL114726 A IL 114726A
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical composition
- compound
- mammal
- noribogaine
- group
- Prior art date
Links
- RAUCDOKTMDOIPF-UHFFFAOYSA-N hydroxyibogamine Natural products CCC1CC(C2)CC3C1N2CCC1=C3NC2=CC=C(O)C=C12 RAUCDOKTMDOIPF-UHFFFAOYSA-N 0.000 title claims abstract description 45
- RAUCDOKTMDOIPF-RYRUWHOVSA-N noribogaine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=C(O)C=C12 RAUCDOKTMDOIPF-RYRUWHOVSA-N 0.000 title claims abstract description 32
- 239000000126 substance Substances 0.000 title claims description 40
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 24
- 235000019788 craving Nutrition 0.000 title claims description 14
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 title claims description 5
- 150000002148 esters Chemical class 0.000 title description 6
- -1 noribogaine compound Chemical class 0.000 claims abstract description 23
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 9
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
- 239000001257 hydrogen Substances 0.000 claims abstract description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 5
- 238000001727 in vivo Methods 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 38
- 241000124008 Mammalia Species 0.000 claims description 36
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims description 20
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 12
- 229960003920 cocaine Drugs 0.000 claims description 10
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims description 8
- 229960002069 diamorphine Drugs 0.000 claims description 8
- 229960002715 nicotine Drugs 0.000 claims description 8
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims description 8
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 7
- 229960001948 caffeine Drugs 0.000 claims description 7
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 7
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 6
- 229940025084 amphetamine Drugs 0.000 claims description 6
- 229960005181 morphine Drugs 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- IUAXSWPNEQYKDR-GXTZACRKSA-N (4R,4aR,7aR,12bS)-9-methoxy-3-methyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinolin-7-one 2,3-dihydroxybutanedioic acid dihydrate Chemical compound O.O.OC(C(O)C(O)=O)C(O)=O.COc1ccc2C[C@@H]3[C@@H]4CCC(=O)[C@@H]5Oc1c2[C@]45CCN3C IUAXSWPNEQYKDR-GXTZACRKSA-N 0.000 claims description 5
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 claims description 5
- 229940104084 hycodan Drugs 0.000 claims description 5
- 229960001797 methadone Drugs 0.000 claims description 5
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims description 5
- 229960001252 methamphetamine Drugs 0.000 claims description 5
- 239000008896 Opium Substances 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 229960001027 opium Drugs 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 206010013663 drug dependence Diseases 0.000 claims description 2
- 208000011117 substance-related disease Diseases 0.000 claims description 2
- 206010012335 Dependence Diseases 0.000 claims 3
- 210000000481 breast Anatomy 0.000 claims 3
- 125000001145 hydrido group Chemical group *[H] 0.000 claims 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- HSIBGVUMFOSJPD-CFDPKNGZSA-N ibogaine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=C(OC)C=C12 HSIBGVUMFOSJPD-CFDPKNGZSA-N 0.000 description 49
- AREITJMUSRHSBK-UHFFFAOYSA-N ibogamine Natural products CCC1CC2C3CC1CN2CCc4c3[nH]c5ccccc45 AREITJMUSRHSBK-UHFFFAOYSA-N 0.000 description 49
- VOXIUXZAOFEFBL-UHFFFAOYSA-N Voacangin Natural products CCC1CC2CN3CC1C(C2)(OC(=O)C)c4[nH]c5ccc(OC)cc5c4C3 VOXIUXZAOFEFBL-UHFFFAOYSA-N 0.000 description 48
- OLOCMRXSJQJJPL-UHFFFAOYSA-N ibogaine Natural products CCC1CC2CC3C1N(C2)C=Cc4c3[nH]c5ccc(OC)cc45 OLOCMRXSJQJJPL-UHFFFAOYSA-N 0.000 description 48
- 239000000203 mixture Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 11
- 229930013930 alkaloid Natural products 0.000 description 8
- 230000036470 plasma concentration Effects 0.000 description 8
- 102000003914 Cholinesterases Human genes 0.000 description 5
- 108090000322 Cholinesterases Proteins 0.000 description 5
- 241001246918 Tabernanthe iboga Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000002045 lasting effect Effects 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 150000001263 acyl chlorides Chemical class 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 229940048961 cholinesterase Drugs 0.000 description 3
- 239000000380 hallucinogen Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- BXNJHAXVSOCGBA-UHFFFAOYSA-N Harmine Chemical compound N1=CC=C2C3=CC=C(OC)C=C3NC2=C1C BXNJHAXVSOCGBA-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- 102100024304 Protachykinin-1 Human genes 0.000 description 2
- 101800003906 Substance P Proteins 0.000 description 2
- UCIDWKVIQZIKEK-NXWOVTFFSA-N Tabernanthine Chemical compound N1([C@@H]2[C@H]3C[C@@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC(OC)=CC=C12 UCIDWKVIQZIKEK-NXWOVTFFSA-N 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229930005303 indole alkaloid Natural products 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- UCIDWKVIQZIKEK-UHFFFAOYSA-N tabernanthine Natural products CCC1CC(C2)CC3C1N2CCC1=C3NC2=CC(OC)=CC=C12 UCIDWKVIQZIKEK-UHFFFAOYSA-N 0.000 description 2
- 238000006257 total synthesis reaction Methods 0.000 description 2
- APJYDQYYACXCRM-UHFFFAOYSA-N tryptamine Chemical compound C1=CC=C2C(CCN)=CNC2=C1 APJYDQYYACXCRM-UHFFFAOYSA-N 0.000 description 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- RERZNCLIYCABFS-UHFFFAOYSA-N Harmaline hydrochloride Natural products C1CN=C(C)C2=C1C1=CC=C(OC)C=C1N2 RERZNCLIYCABFS-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- ZAGRKAFMISFKIO-UHFFFAOYSA-N Isolysergic acid Natural products C1=CC(C2=CC(CN(C2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-UHFFFAOYSA-N 0.000 description 1
- 102000004108 Neurotransmitter Receptors Human genes 0.000 description 1
- 108090000590 Neurotransmitter Receptors Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- WYTGDNHDOZPMIW-RCBQFDQVSA-N alstonine Chemical compound C1=CC2=C3C=CC=CC3=NC2=C2N1C[C@H]1[C@H](C)OC=C(C(=O)OC)[C@H]1C2 WYTGDNHDOZPMIW-RCBQFDQVSA-N 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- KDDCNSWPVMLDHI-UHFFFAOYSA-N azepino[3,2-b]indole Chemical class C1=CC=CN=C2C3=CC=CC=C3N=C21 KDDCNSWPVMLDHI-UHFFFAOYSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 231100000313 clinical toxicology Toxicity 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 230000003400 hallucinatory effect Effects 0.000 description 1
- VJHLDRVYTQNASM-UHFFFAOYSA-N harmine Natural products CC1=CN=CC=2NC3=CC(=CC=C3C=21)OC VJHLDRVYTQNASM-UHFFFAOYSA-N 0.000 description 1
- LRLCVRYKAFDXKU-YGOSVGOTSA-N ibogamine Chemical compound N1([C@@H]2[C@H]3C[C@H](C1)C[C@@H]2CC)CCC1=C3NC2=CC=CC=C12 LRLCVRYKAFDXKU-YGOSVGOTSA-N 0.000 description 1
- DQOMBBVESFBJLX-VXLUQLENSA-N iboluteine Chemical compound N1C2=CC=C(OC)C=C2C(=O)[C@@]21CCN(C1)[C@H]3[C@@H]2C[C@@H]1C[C@H]3CC DQOMBBVESFBJLX-VXLUQLENSA-N 0.000 description 1
- DQOMBBVESFBJLX-UHFFFAOYSA-N iboluteine Natural products N1C2=CC=C(OC)C=C2C(=O)C21CCN(C1)C3C2CC1CC3CC DQOMBBVESFBJLX-UHFFFAOYSA-N 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- ZAGRKAFMISFKIO-QMTHXVAHSA-N lysergic acid Chemical compound C1=CC(C2=C[C@H](CN([C@@H]2C2)C)C(O)=O)=C3C2=CNC3=C1 ZAGRKAFMISFKIO-QMTHXVAHSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001962 neuropharmacologic effect Effects 0.000 description 1
- KJONHKAYOJNZEC-UHFFFAOYSA-N nitrazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1 KJONHKAYOJNZEC-UHFFFAOYSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940117803 phenethylamine Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 239000003762 serotonin receptor affecting agent Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28018794A | 1994-07-25 | 1994-07-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL114726A0 IL114726A0 (en) | 1995-11-27 |
| IL114726A true IL114726A (en) | 2002-04-21 |
Family
ID=23072046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL11472695A IL114726A (en) | 1994-07-25 | 1995-07-25 | Pharmaceutical compositions containing 12-hydroxyibogamine or an ester thereof for treatment of craving for and dependency on chemical substances and withdrawal symptoms and the novel esters of 12-hydroxyibogamine |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6348456B1 (de) |
| EP (1) | EP0804200B1 (de) |
| AT (1) | ATE324897T1 (de) |
| AU (1) | AU4613296A (de) |
| DE (1) | DE69534975T2 (de) |
| DK (1) | DK0804200T3 (de) |
| ES (1) | ES2264562T3 (de) |
| IL (1) | IL114726A (de) |
| MX (1) | MX9701430A (de) |
| PT (1) | PT804200E (de) |
| WO (1) | WO1996003127A1 (de) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7220737B1 (en) | 1997-09-04 | 2007-05-22 | Novoneuron, Inc | Noribogaine in the treatment of pain and drug addiction |
| AU2003200404B2 (en) * | 1997-09-04 | 2006-06-29 | Demerx, Inc. | Noribogaine in the treatment of pain and drug addiction |
| ES2224430T3 (es) * | 1997-09-04 | 2005-03-01 | Novoneuron Inc | Noribogaina en el tratamiento del dolor y de la toxicomania. |
| BR0106261A (pt) * | 2001-12-26 | 2003-09-02 | Fundacao Oswaldo Cruz | Composições medicamentosas contendo alcalóides indólicos para o tratamento da aids |
| US20030153552A1 (en) * | 2002-02-14 | 2003-08-14 | Mash Deborah C. | Method of treating chemical dependency in mammals and a composition therefor |
| GB2480632A (en) | 2010-05-25 | 2011-11-30 | Kythera Biopharmaceuticals Inc | Preparation of 12-keto and 12-alpha-hydroxy steroids |
| US8362007B1 (en) | 2010-05-11 | 2013-01-29 | Demerx, Inc. | Substituted noribogaine |
| US9394294B2 (en) | 2010-05-11 | 2016-07-19 | Demerx, Inc. | Methods and compositions for preparing and purifying noribogaine |
| US8765737B1 (en) | 2010-05-11 | 2014-07-01 | Demerx, Inc. | Methods and compositions for preparing and purifying noribogaine |
| US8741891B1 (en) | 2010-06-22 | 2014-06-03 | Demerx, Inc. | N-substituted noribogaine prodrugs |
| US8802832B2 (en) | 2010-06-22 | 2014-08-12 | Demerx, Inc. | Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier |
| US8637648B1 (en) | 2010-06-22 | 2014-01-28 | Demerx, Inc. | Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier |
| US9586954B2 (en) | 2010-06-22 | 2017-03-07 | Demerx, Inc. | N-substituted noribogaine prodrugs |
| CA2806232A1 (en) * | 2010-07-23 | 2012-01-26 | Demerx, Inc. | Noribogaine compositions |
| AU2012202509B2 (en) * | 2010-07-23 | 2014-02-13 | Demerx, Inc. | Noribogaine compositions |
| EP2481740B1 (de) | 2011-01-26 | 2015-11-04 | DemeRx, Inc. | Verfahren und Zusammensetzungen zur Herstellung von Noribogain aus Voacangin |
| US9617274B1 (en) | 2011-08-26 | 2017-04-11 | Demerx, Inc. | Synthetic noribogaine |
| US9040520B2 (en) * | 2011-09-15 | 2015-05-26 | Demerx, Inc. | Noribogaine salt ansolvates |
| WO2013085850A2 (en) | 2011-12-08 | 2013-06-13 | Demerx, Inc. | Stereoselective total synthesis of noribogaine |
| CA2855990A1 (en) * | 2011-12-09 | 2013-06-13 | Demerx, Inc. | Sulfate esters of noribogaine |
| WO2013085922A1 (en) * | 2011-12-09 | 2013-06-13 | Demerx, Inc. | Phosphate esters of noribogaine |
| WO2013112163A1 (en) * | 2012-01-25 | 2013-08-01 | Demerx, Inc. | Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them |
| WO2013112673A1 (en) | 2012-01-25 | 2013-08-01 | Demerx, Inc. | Synthetic voacangine |
| US9150584B2 (en) | 2012-01-25 | 2015-10-06 | Demerx, Inc. | Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them |
| EP2934541A4 (de) * | 2012-12-20 | 2016-08-03 | Demerx Inc | Substituiertes noribogain |
| US9045481B2 (en) | 2012-12-20 | 2015-06-02 | Demerx, Inc. | Substituted noribogaine |
| CA2942638C (en) | 2013-03-15 | 2026-03-10 | Demerx, Inc. | Method for noribogaine treatment of addiction in patients on methadone |
| AU2014379612A1 (en) * | 2014-01-24 | 2016-08-11 | Demerx, Inc. | Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier |
| EA201691656A2 (ru) * | 2014-02-18 | 2017-03-31 | Демеркс, Инк. | Терапевтические способы с применением норибогаина и родственных соединений |
| EA201691647A1 (ru) | 2014-02-18 | 2017-01-30 | Демеркс, Инк. | Способы кратковременного и долгосрочного лечения зависимости от лекарственных средств |
| US9561232B2 (en) | 2014-02-18 | 2017-02-07 | Demerx, Inc. | Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use |
| US9591978B2 (en) | 2014-03-13 | 2017-03-14 | Demerx, Inc. | Methods and compositions for pre-screening patients for treatment with noribogaine |
| US9550789B2 (en) | 2014-06-18 | 2017-01-24 | Demerx, Inc. | Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them |
| US9549935B2 (en) | 2014-07-14 | 2017-01-24 | Demerx, Inc. | Methods and compositions for treating migraines using noribogaine |
| ES2867174T3 (es) | 2014-11-26 | 2021-10-20 | Demerx Inc | Métodos y composiciones para potenciar la acción de analgésicos opioides mediante el uso de alcaloides de iboga |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| KR20220008824A (ko) | 2019-04-17 | 2022-01-21 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 |
| GB2611705B (en) | 2019-07-15 | 2024-03-27 | Demerx Inc | Methods for the non-toxic treatment for opioid drug withdrawal combining noribogaine and cannabinoids |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3516989A (en) * | 1967-10-02 | 1970-06-23 | American Home Prod | Intermediates for total synthesis of iboga alkaloids and means of preparation |
| US4499096A (en) * | 1983-11-18 | 1985-02-12 | Lotsof Howard S | Rapid method for interrupting the narcotic addiction syndrome |
| US4587243A (en) * | 1985-07-15 | 1986-05-06 | Lotsof Howard S | Rapid method for interrupting the cocaine and amphetamine abuse syndrome |
| US5152994A (en) * | 1990-05-31 | 1992-10-06 | Lotsof Howard S | Rapid method for interrupting or attenuating poly-drug dependency syndromes |
| US5591738A (en) * | 1994-10-14 | 1997-01-07 | Nda International, Inc. | Method of treating chemical dependency using β-carboline alkaloids, derivatives and salts thereof |
-
1995
- 1995-07-25 WO PCT/US1995/009136 patent/WO1996003127A1/en not_active Ceased
- 1995-07-25 MX MX9701430A patent/MX9701430A/es not_active IP Right Cessation
- 1995-07-25 EP EP95927295A patent/EP0804200B1/de not_active Expired - Lifetime
- 1995-07-25 IL IL11472695A patent/IL114726A/en not_active IP Right Cessation
- 1995-07-25 AT AT95927295T patent/ATE324897T1/de not_active IP Right Cessation
- 1995-07-25 AU AU46132/96A patent/AU4613296A/en not_active Abandoned
- 1995-07-25 DK DK95927295T patent/DK0804200T3/da active
- 1995-07-25 DE DE69534975T patent/DE69534975T2/de not_active Expired - Lifetime
- 1995-07-25 ES ES95927295T patent/ES2264562T3/es not_active Expired - Lifetime
- 1995-07-25 PT PT95927295T patent/PT804200E/pt unknown
-
1996
- 1996-10-08 US US08/727,123 patent/US6348456B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU4613296A (en) | 1996-04-19 |
| WO1996003127A1 (en) | 1996-02-08 |
| PT804200E (pt) | 2006-09-29 |
| US6348456B1 (en) | 2002-02-19 |
| ATE324897T1 (de) | 2006-06-15 |
| ES2264562T3 (es) | 2007-01-01 |
| DE69534975D1 (de) | 2006-06-08 |
| MX9701430A (es) | 1997-12-31 |
| EP0804200A1 (de) | 1997-11-05 |
| IL114726A0 (en) | 1995-11-27 |
| DK0804200T3 (da) | 2006-09-11 |
| EP0804200A4 (de) | 1999-06-23 |
| DE69534975T2 (de) | 2007-01-11 |
| EP0804200B1 (de) | 2006-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0804200B1 (de) | Verwendung von noribogain derivaten zur behandlung von chemischer abhängigkeit bei säugern | |
| US20030153552A1 (en) | Method of treating chemical dependency in mammals and a composition therefor | |
| WO2021155468A1 (en) | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders | |
| US5591738A (en) | Method of treating chemical dependency using β-carboline alkaloids, derivatives and salts thereof | |
| CN102718710B (zh) | 吗啡烷化合物 | |
| CA1237986A (en) | Rapid method of interrupting the narcotic addiction syndrome | |
| EP0236684A2 (de) | Galanthamin oder dessen Analoge zur Behandlung der Alzheimerschen Krankheit | |
| CN110831584B (zh) | 具有新颖的组合物、组合的靶向药物拯救及其方法 | |
| AU2006268098B2 (en) | Use of 3,1IB-CIS-dihydrotetrabenazine for the treatment of symptoms of Huntington's disease | |
| AU658730B2 (en) | Epibatidine and derivatives, compositions and methods of treating pain | |
| Zhang et al. | Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease | |
| WO2011133212A1 (en) | Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders | |
| US5169852A (en) | Method of suppressing appetite by administration of tetrahydro-beta-carboline derivatives | |
| KR20000042507A (ko) | 콜레스테롤 생합성 저해효과를 나타내는 디벤조[a,g]퀴놀리지늄 유도체 | |
| CN104812754A (zh) | 四氢原小檗碱化合物及其在治疗神经、精神和退行性神经疾病中的应用 | |
| RU2738648C2 (ru) | Применение соединения для лечения хронической тревоги или острой тревоги | |
| EA008907B1 (ru) | Производные индола | |
| EP1501520A1 (de) | Pharmazeutische zubereitung zur reduktion des glucose- und cholesterin-spiegels im blut | |
| JP4761683B2 (ja) | 置換５−オキソ−５，６，７，８−テトラヒドロ−４ｈ−１−ベンゾピランおよびベンゾチオピランならびにそのａｍｐａ増強剤としての使用 | |
| Watanabe et al. | Effects on central dopaminergic systems of d-coclaurine and d-reticuline, extracted from Magnolia salicifolia | |
| JPH085863B2 (ja) | １４−アニソイルアコニンおよびそれを有効成分とする新規な鎮痛・抗炎症剤 | |
| RU2073678C1 (ru) | (s)-1-[(10-хлор-6,7-дигидро-4-оксо-3-фенил-4h-бензо/а/хинолизин-1-ил)карбонил]-3-этоксипирролидин, (s)-1-[(10-хлор-6,7-дигидро-4-оксо-3-фенил-4h-бензо/а/хинолизин-1-ил)карбонил]-3-оксипирролидин в качестве промежуточного продукта, композиция, обладающая гипнотическим неседативным действием | |
| Jacob III et al. | Oxidative metabolism of nicotine in vivo | |
| JP3535207B2 (ja) | 抗ガン剤及びｇｒｐレセプター拮抗剤 | |
| US4332807A (en) | N-Substituted-benzyl-11-endo-amino-5,6,7,8,9,10-hexahydro-2-hydroxy (or methoxy)-6,9-methanobenzocyclooctene (or nonene) centrally-acting analgesics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |